Page last updated: 2024-11-13
globotetraose
Description
beta-D-GalpNAc-(1->3)-alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-D-Glcp : A linear amino tetrasaccharide consisting of D-glucose at the reducing end having an N-acetyl-beta-D-galactosaminyl-(1->3)-alpha-D-galactosyl-(1->4)-beta-D-galactosyl moiety attached at the 4-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (12)
Synonym |
(gal)2 (galnac)1 (glc)1 |
globotetraose |
n-acetyl-beta-d-galactosaminyl-(1->3)-alpha-d-galactosyl-(1->4)-beta-d-galactosyl-(1->4)-d-glucose |
beta-d-galpnac-(1->3)-alpha-d-galp-(1->4)-beta-d-galp-(1->4)-d-glcp |
galnacbeta1-3galalpha1-4galbeta1-4glc |
CHEBI:63013 |
galnacbeta1-3galalpha1-4galbeta1-4glc~oh |
beta-d-galnac-(1->3)-alpha-d-gal-(1->4)-beta-d-gal-(1->4)-d-glc |
2-acetamido-2-deoxy-beta-d-galactopyranosyl-(1->3)-alpha-d-galactopyranosyl-(1->4)-beta-d-galactopyranosyl-(1->4)-d-glucopyranose |
W-203733 |
JMPCSGHAAIDYIN-WASRWFGHSA-N |
Q27132335 |
Drug Classes (2)
Class | Description |
amino tetrasaccharide | A tetrasaccharide derivative having one or more substituted or unsubstituted amino groups in place of hydroxy groups at unspecified positions. |
galactosamine oligosaccharide | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (17)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 2 (11.76) | 18.7374 |
1990's | 5 (29.41) | 18.2507 |
2000's | 8 (47.06) | 29.6817 |
2010's | 2 (11.76) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 2 (11.11%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 16 (88.89%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |